Abstract:
The present invention relates to a method for reinforcing a barrier function of a cell, by reinforcing the function or increasing gene expression by having an NADPH-quinone-oxidoreductase-1 (NQO1) gene or a protein expressed therefrom, as a target molecule. More specifically, the present invention is based on a cell barrier function relating to worsening of an inflammation of a large intestine epithelial cell of a human or a mammal, and an NQO1 gene adjusting the cell barrier function, to suppress the worsening of the inflammation caused by a loss of the barrier function of the large intestine epithelial cell and provide a treatment for effectively treating various acute and chronic enteritis diseases.
Abstract:
PURPOSE: A composition for suppressing immunocytes containing a coprisin peptide derivative, CopA3(9-mer disulfide dimer), as an active ingredient is provided to significantly suppress activation of macrophage without side effects such as cytotoxicity, and to develop a novel therapeutic agent for treating immune diseases including arteriosclerosis and rheumatoid arthritis. CONSTITUTION: A composition for suppressing immunocytes contains a coprisin peptide derivative, CopA3(9-mer disulfide dimer), as an active ingredient. The derivative is a regulator which suppresses activation of immunocytes. The immunocytes are macrophage. The derivative is D-type and is derived from an insect. The derivative is used for treating immune diseases including arteriosclerosis and rheumatoid arthritis.
Abstract:
PURPOSE: A composition containing coprisin peptide derivative CopA3(HL) for treating Pseudomembranous colitis is provided to prevent antibiotics effect to helpful microbes such as Bifidobacterium and Lactobacillus. CONSTITUTION: A composition for treating Pseudomembranous colitis contains coprisin peptide derivative CopA3(HL) as an active ingredient. The coprisin peptide derivative CopA3(HL) has an amino acid sequence(L-L-C-I-A-L-R-K-K). The coprisin peptide derivative suppresses Clostrdium difficile in the large intestine. The coprisin peptide derivative CopA3(HL) is D-type.